Novohope to Bring Pet Oral Film Supplements to Cannafest Prague 2026

Wuxi-based pet nutrition brand to present its oral dissolvable film range at the international cannabis and medicinal herbs trade show

CALIFORNIA, CA, UNITED STATES, October 23, 2026 /EINPresswire.com/ — Prague  |  23 October 2026  |  Health & Medicine

PRAGUE — Novohope, a pet health supplement brand, is scheduled to exhibit at Cannafest Prague 2026, to be held from 6 to 8 November 2026 at the PVA Expo in Prague. The company said it will present its orally disintegrating film (ODF) and orally disintegrating tablet (ODT) range for dogs and cats to European distributors, private-label brand owners and retail buyers, and describes the appearance as its entry point into Central and Eastern European markets.

Novohope is a pet health supplement brand whose portfolio covers eye care and tear-stain management, coat and skin condition, digestive support, joint and mobility care, cardiovascular maintenance, weight management and calming. Its products are supplied as single-unit oral formats that dissolve in the mouth, rather than as powders, tablets or chewable treats.
Industry context

Third-party market estimates place the global pet supplements market at approximately USD 2.8 billion in 2025, with Grand View Research projecting growth to USD 4.6 billion by 2033. Mordor Intelligence estimates the narrower pet dietary supplements segment at USD 5.11 billion by 2026, growing at a compound annual rate of 7.42% through 2031. The two estimates differ in category definition and are not directly comparable.

Grand View Research data indicates North America accounted for 48.1% of global pet supplement revenue in 2025. Mordor Intelligence identifies Asia-Pacific as the fastest-growing region, citing rising pet humanisation and healthcare spending in China and India.

Oral dissolvable film is an emerging delivery format in the pet sector. Market Reports World notes that development work in this segment focuses on disintegration times below 25 seconds and palatability improvements of up to 47% through taste masking. In the United States, the National Animal Supplement Council (NASC) Quality Seal functions as a reference standard for the category, requiring adherence to Good Manufacturing Practices and labelling audits.

Product range scheduled for display

The portfolio planned for the Prague exhibition comprises seven stock-keeping units, each in a fixed single-unit dose format:

EYES+ — ODF, 2.1 g / 0.074 oz, formulated for eye care and tear-stain management, with lutein and zeaxanthin among the listed ingredients.

COAT+ — ODF, 2.5 g / 0.088 oz, 10 films per pack, formulated for coat and skin condition, with sodium hyaluronate, DHA and biotin listed.

BONE+ — ODT, 2.1 g (10 pcs), joint and mobility support; glucosamine HCl 100 mg, hydrolysed collagen peptides 90 mg and undenatured type II collagen (UC-II) per unit.

HEART+ — ODT, 2.1 g (10 pcs), cardiovascular maintenance; taurine 50 mg, L-carnitine 35 mg, coenzyme Q10 10 mg and vitamin E 5 IU.

PROBIO — ODT, 2.5 g (10 pcs), digestive support; Bacillus coagulans (GBI-30, 6086) at 1×10^9 CFU and pasteurised Akkermansia muciniphila (postbiotic) 12 mg, alongside GOS and XOS.

CALM+ — ODT, 2.5 g / 0.088 oz (10 films), calming support; α-casozepine 100 mg, L-theanine 50 mg and Pediococcus acidilactici CCFM6432 at 1×10^9 CFU.

FIT+ — ODT (10 pcs), formulated for weight management.

Because the active content is fixed per film or tablet, the format removes the measuring step that applies to powders mixed into food, where intake depends on the owner’s dosing accuracy. The trade-off is that each SKU is tied to a defined daily unit, so the range has to be matched to the animal’s weight band and condition at the point of sale.

Claimed performance and what is documented

Novohope states that its films dissolve within 10 seconds of contact with saliva, and that active ingredients are absorbed through the oral mucosa rather than through the gastrointestinal tract. The company cites an absorption rate of up to 95% for the mucosal route, compared with approximately 35% for conventional supplement formats. These figures are company-reported and have not been independently verified.

What third-party documentation covers is narrower: manufacturing registration, hazard communication data sheets and ingredient composition analyses for individual SKUs. Buyers evaluating the format should separate the two categories of evidence, since absorption claims and composition testing answer different questions.

Compliance file submitted by the company

The documentation referenced for the range includes:

U.S. FDA Food Facility Registration number 18753066908, issued 1 July 2026 and valid to 31 December 2026, under Section 305 of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, listed under Wuxi Nuohui Biotechnology Co., Ltd.

Safety Data Sheets issued under OSHA Hazard Communication Standard 29 CFR 1910.1200 (HCS): DTI2026EC060626-5 (BONE+ scope), DTI2026EC060626-1 (COAT+ scope) and DTI2026EC060626-2 (EYES+ scope).

Test report DTI2026EC050626-2-2 confirming compliance with US FDA 21 CFR 175.300 for EYES+ Eye Care & Tear Stain Care.

Certificate of Analysis DTI2026EC050626-4 covering HEART+ Cardiovascular Care, and test report DTI2026EC050626-1 covering COAT+ Coat Care & Shiny Hair.

Four trademark application acceptance notices filed with the National Intellectual Property Administration in China on 12 February 2026, under acceptance numbers 89737106 (‘NovoHope’, Class 31), 89737105 (Class 31), 89737107 (Class 7) and 89737108 (Class 7).

The testing documents listed above were issued by Shenzhen Deesev Testing International Corporation. Two limits should be noted by buyers: the FDA entry is a facility registration, not a product approval, and the Chinese filings are acceptance notices for pending applications rather than granted registrations. Any distributor presenting these documents in a European retail listing should describe them accordingly.

Manufacturing terms and OEM constraints

For private-label and ODM buyers, the company’s stated commercial terms are a minimum order quantity of 3,000 units per SKU and a lead time of 35 to 45 days, against a stated monthly capacity of 200,000,000 units. Customisation is offered on recipe, brand and packaging design. Quality control is described as 100% inspection before delivery, supplemented by third-party sampling tests. Named export markets are Europe, North America, Southeast Asia, the Middle East and East Asia, with remote after-sales support.

The company reports a three-year private-label and ODM programme with an EM client across Germany, the United Arab Emirates, Canada, Australia, France and the United States, covering 200,000 units for chain supermarket and retail distribution. The reported outcome was category sales growth and repeat orders. The volume and outcome are company-reported.

For a European buyer, the practical constraint is not capacity but sequence: recipe confirmation, packaging artwork, third-party testing and the 35 to 45 day production window together define the earliest realistic shelf date, and multi-SKU launches stack rather than run in parallel under a 3,000-unit-per-SKU threshold.

Market impact

Central and Eastern Europe has been a secondary destination for Asian pet supplement suppliers relative to Western European markets, and trade exhibitions in the region are used mainly for distributor identification rather than direct consumer sales. Novohope’s stated objective in Prague is commercial: establishing links with regional partners and raising brand recognition among trade buyers.

Format differentiation is the commercial argument the company is making. Conventional pet supplements in Europe are dominated by tablets, powders and chewables, where the purchase decision is driven largely by ingredient content and price per dose. A dissolving film competes instead on administration and compliance, which matters where owners stop supplementing because the animal refuses the product.

Regulatory status is market-specific. Feed and labelling requirements for animal supplements differ between EU member states, and product classification, permitted claims and label content are typically verified per market before listing. No EU-wide authorisation is asserted for the range.

Third-party read

Published market data supports the direction of travel rather than any individual company’s position. The category is growing in single digits to low double digits depending on definition, and oral film remains a small share of it. The National Animal Supplement Council standard in the United States indicates that quality seals and manufacturing audits, rather than delivery format, remain the primary trust mechanism for buyers in this segment.

No public data reviewed establishes Novohope’s market share, and none is claimed here. The company’s own positioning references a technical background in oral film formulation and a seven-SKU portfolio; those are company statements, and the verifiable elements are the registration, testing and trademark records listed above.

Outlook

Three developments are worth tracking after the Prague exhibition: whether the company converts trade contacts into named distribution agreements in Central and Eastern Europe; whether additional market registrations follow the existing U.S. facility registration and Chinese trademark filings; and whether the film format reaches price parity with conventional formats at retail, which would determine whether it moves from a premium niche into mainstream shelf space.

Novohope said it will continue to develop products within the pet health category and to extend distribution beyond its current export markets. No financial targets or volume forecasts were disclosed.

Frank
Wuxi Novohope Biotechnology Co., Ltd.
+ +86 1626 232 2952
NovoHope.pet@outlook.com
Visit us on social media:
Other

Media gallery